This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Abeona Therapeutics, Inc.
Description: Abeona is developing an adeno-associated virus (AAV) gene therapy program expressing LK19 FANCC for the treatment of Fanconi anemia.
Stanford and Abeona
In September 2015, Abeona announced a license agreement with Stanford University for an AAV (adeno-associated virus) delivery vector for the treatment of Fanconi anemia (FA) and rare blood disease platform.
AAV-FANCC (Stanford) News
Additional information available to subscribers only: